Trial Profile
A Study to Evaluate the Efficacy of Aflibercept in Patients With Ranibizumab-Resistant Exudative Age-Related Macular Degeneration (AMD) With and Without Choroidal Vascular Hyperpermeability (CVH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 08 Mar 2016 New trial record